Two basic TME profiles can be distinguished: “hot” immune-inflamed TME that is associated with higher densities of CD8+ tumor-infiltrating lymphocytes (TILs), accompanied by myeloid cells and monocytic cells, higher levels of IFN and IFN stimulated chemokines such as CXCL9, CLCL10 and CXCL11 present and various other proinflammatory and effector cytokines may predict benefit from PD-1 blockade therapy. The gene discussed is IFNA1; the disease is neoplasm.